Strategic partnerships Leverage Serametrix’s established collaborations with LICR, LICR-affiliated researchers, and prominent cancer centers like MSK to position complementary immunoassay services within joint clinical trials and translational research programs.

Immuno-monitoring expertise Highlight the company’s specialized immune monitoring packages that quantify anti-tumor immunity, offering a compelling value proposition to pharma sponsors seeking robust biomarker strategies for immunotherapy trials.

Market niche Target small-to-mid biotech and oncology-focused sponsors with limited in-house immunoassay capabilities, presenting Serametrix as a scalable, disease-area expert partner for trial-ready immune profiling.

Acquisition opportunity Note historical acquisition by Caprion Biosciences as a potential exit or collaboration channel; approach potential buyers or strategic partners with a clear integration plan highlighting standardized assays and access to proven technologies.

Growth channels Position Serametrix to capitalize on the growing demand for immune monitoring in clinical trials by offering streamlined data delivery, assay standardization, and actionable readouts that accelerate drug development timelines for oncology sponsors.